YOU ARE NOW LEAVING IDERACLINICALTRIALS.COM
The goal of the Illuminate 301 clinical trial is to evaluate the comparison of FDA approved Yervoy® (ipilimumab) alone and Yervoy® (ipilimumab) together with tilsotolimod (IMO-2125) in patients with metastatic melanoma who have shown signs of disease progression while on Opdivo® (nivolumab) or Keytruda® (pembrolizumab).
*Additional eligibility criteria apply. Please contact your doctor for more detailed information about the study.
Yervoy® and Opdivo® are registered trademarks of Bristol-Myers Squibb. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
If you are enrolled in the study, you will be assigned by chance to 1 of 2 treatment groups—group A or group B. If enrolled, you have an equal chance of being assigned to either group.
Group A patients will receive Yervoy up to 4 times.
Group B patients will receive tilsotolimod up to 9 times, 4 of which will be in combination with Yervoy.
*Yervoy® is a registered trademark of Bristol-Myers Squibb Company.
You may be eligible to participate in the study if you*
Before you can be enrolled in a study, you must undergo a process called screening, during which the study team will evaluate whether you qualify to participate.
*Additional eligibility criteria apply. Please speak to your doctor for more detailed information about the study.
Yervoy® and Opdivo® are registered trademarks of Bristol-Myers Squibb Company. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.